Literature DB >> 2271400

Racial differences in antihypertensive therapy: evidence and implications.

M H Weinberger1.   

Abstract

Blood pressure is controlled by many factors, and thus hypertension is a multifactorial disorder. This etiologic diversity is also reflected in the broad spectrum of different pharmacologic agents known to lower blood pressure. Most carefully controlled studies employing a single antihypertensive drug in unselected, uncomplicated mild to moderate hypertensives demonstrate efficacy in reducing blood pressure in 40-60% of the population. If two agents of differing pharmacologic actions are combined, success rates of 70-90% are generally observed. Specific choices of antihypertensive agents have heretofore been based on whimsy, hearsay, or empiricism. More recent studies have identified characteristics that may help to predict the efficacy of single drugs. These characteristics have included physiologic factors, such as sodium sensitivity, plasma renin activity, or sympathetic nervous system activity, as well as demographic components, particularly age and race. This review will examine the effects of racial classification on the blood pressure response to antihypertensive agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271400     DOI: 10.1007/bf02603180

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  48 in total

1.  Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.

Authors:  S B Levy; J J Lilley; R P Frigon; R A Stone
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

3.  Incidence of suppressed renin activity and of normokalemic primary aldosteronism in hypertensive Negro patients.

Authors:  M C Creditor; U K Loschky
Journal:  Circulation       Date:  1968-06       Impact factor: 29.690

4.  Responses to captopril and hydrochlorothiazide in black patients with hypertension.

Authors:  M Moser; J Lunn
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

5.  Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.

Authors:  M H Weinberger
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

6.  Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.

Authors:  M H Weinberger
Journal:  Arch Intern Med       Date:  1985-06

7.  Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk.

Authors:  M H Weinberger
Journal:  Am J Med       Date:  1986-02-14       Impact factor: 4.965

8.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

9.  Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.

Authors:  F C Luft; G R Aronoff; R S Sloan; N S Fineberg; M H Weinberger
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

10.  Labetalol as monotherapy in hypertensive black patients.

Authors:  R B Cubberley
Journal:  J Clin Hypertens       Date:  1985-12       Impact factor: 3.738

View more
  5 in total

1.  First line treatment in hypertension.

Authors: 
Journal:  BMJ       Date:  1991-01-12

Review 2.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.

Authors:  T Baba; T Kodama; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.